Toll Free 1-800-300-2919

Request Your Free Mesothelioma Book

  • Check here if you or someone you know has mesothelioma:
  • Has a biopsy been performed?
  • What is the current treatment plan?

Real Answers For Those With Mesothelioma

  • Get the Latest Treatment Options
  • Connect with Top Doctors and Specialists
  • Learn About Financial and Legal Assistance
  • See the Latest Information for Veterans

packet of books and informational pamphlets on Mesothelioma

Emerging Therapy Watch: NGR-hTNF for MPM, Phase III Trial

An emerging therapy known as NGR-hTNF has entered an ongoing phase III trial that has nearly 400 participants at 49 hospitals and research centers around the world. NGR-hTNF is defined by the National Cancer Institute (NCI) as a substance that is made by linking tumor necrosis factor (TNF) to a peptide. The peptide binds to tumor blood vessels, and TNF damages them. Also called “tumor vasculature–targeted tumor necrosis factor alpha” NGR-hTNF is a type of biological response modifier.

The main objective of the NGR-hTNF trial is to document the efficacy of the substance administered at low doses weekly in advanced malignant pleural mesothelioma (MPM) patients previously treated with a pemetrexed-based chemotherapy regimen. Currently, there are no regulatory-approved or widely accepted treatment options for MPM patients failing a standard pemetrexed-based chemotherapy regimen.

The study aims to show “a superior efficacy in terms of overall survival duration of NGR-hTNF 0.8 µg/mq weekly, plus BIC versus placebo plus BIC in advanced MPM patients progressing after a standard pemetrexed-based chemotherapy,” says BIC refers to “Best Investigator’s Choice,” meaning, one of the following single-agent chemotherapy drugs might be administered in combination with NGR-hTNF:

  • Doxorubicin (Adriamycin, Rubex)
  • Gemcitabine (Gemzar)
  • Vinorelbine (Navelbine)

Though the NGR-hTNF study is now classified as “ongoing,” it is not currently recruiting participants. However, if it passes phase III, this promising treatment could become available in the near future.


"FAQ: - Clinical Trial Phases." U.S. National Library of Medicine. National Institutes of Health (NIH), 18 Apr. 2008. Web. 29 Mar. 2017.

"Malignant Mesothelioma - Market Insights, Epidemiology and Market Forecast - 2023 - United States." Research and Markets. Research and Markets, Jan. 2017. Web. 29 Mar. 2017.

"NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed." U.S. National Institutes of Health (NIH), 30 Mar. 2017. Web. 31 Mar. 2017.

"NGR-TNF." National Cancer Institute (NCI). U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH), n.d. Web. 29 Mar. 2017.